Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better Data Tracking Could Hold Key To Indication-Based Pricing Progress

Executive Summary

Indication-based pricing could become a reality with better infrastructure to track utilization data.

You may also be interested in...



Indication-Based Pricing Sparks Interest In UK

Different prices for different medical conditions treated by the same drug and tying drug prices to the benefits they deliver are some of the recommendations made by a cross-sector expert panel to improve patient access to innovative cancer medicines.

Combination Pricing Solution As Elusive As Ever

The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel